Full Press Release Details
On track to implant first patients in long-term, multicenter feasibility study of the fully implantable continuous blood glucose monitor (CBGM) system in Australiain Q3 2025
Investigational Device Exemption submission to FDA of novel CBGM technology in Q4 2025
Strengthened Board of Directors, expands clinical advisory board, and established a Patient Advisory Board
Improved capital structure, cash and cash equivalents expected to fund operations through 2025, including initiation of OUS clinical trials and achievement of related milestones
Rutherford, NJ, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today reported financial results and recent corporate highlights for the six months ended June 30, 2025.
“This quarter, we made meaningful progress across the business, including the expansion of our clinical advisory team with the appointment of Dr. Hirsh, an expert in implantation protocols, as Medical Director - Cardiology, and the election of Dr. Carr-Brendel, a seasoned medical device executive, to our Board of Directors. We also established a Patient Advisory Board to ensure patient perspectives remain central as we continue to refine and advance our CBGM technology. We are also encouraged by the growing momentum and strong interest in our technology, particularly among key opinion leaders, as demonstrated by the standing-room-only audience at our presentation during the ADA conference in June,”said Paul V. Goode, PhD, President and Chief Executive Officer of Glucotrack. “At the same time, we strengthened our capital structure, removing the warrant liability and share dilution overhang which, we believe, creates attractive opportunities for new investors to join in our mission to bring our potentially life-improving technology to the millions of diabetes patients who need it most.”
Dr. Goode continued,“Looking ahead, we are on track to initiate our clinical study in Australia in the third quarter and to continue building our robust body of clinical evidence supporting the use of our well-differentiated, fully implantable, real-time, multi-year CBGM system. We also anticipate submitting our IDE to the FDA in the fourth quarter, enabling in 2026 the launch of our long-term, multicenter Pilot Study in the US.”
Second Quarter 2025 & Recent Highlights
Corporate Highlights
Advanced Product and Clinical Development
Anticipated Milestones in 2025
Financial Results for the year-to-date six months ended June 30, 2025
Research and Development Expenses:Research and development expenses were $5.0 million for the six months ended June 30, 2025, compared to $5.7 million for the prior-year period. The decrease of $0.7 million was primarily due to timing in product and manufacturing development activities.
Marketing, General and Administrative Expenses:Marketing, General and Administrative expenses were $3.3 million for the six months ended June 30, 2025, compared to $1.7 million for the prior-year period. The increase of $1.6 million was primarily attributable to increased legal and professional fees and personnel costs.
Net Loss:Net loss for the six months ended June 30, 2025, was $11.6 million compared to a net loss of $7.4 million for the prior-year period. The increase in net loss is attributable primarily to the non-cash $3.3 million change in fair value of derivative liabilities and increase of $0.9 million in operating expenses.
Cash Position:Cash and cash equivalents as of June 30, 2025, were $9.6 million, compared with $5.6 million in cash and cash equivalents as of December 31, 2024. The net increase in cash and cash equivalents of $4.0 million was attributable to the $10.7 million net proceeds from public equity financings offset by cash used in operating and investing activities of $6.7 million for the first six months of 2025.
Based on current plans and assumptions, the Company believes that its existing cash and cash equivalents will be sufficient to fund its 2025 operating plan to initiate human clinical trials and related milestones.
About Glucotrack, Inc.
Glucotrack, Inc. (Nasdaq: GCTK) is focused on the design, development, and commercialization of novel technologies for people with diabetes. The Company is currently developing a long-term implantable continuous blood glucose monitoring system for people living with diabetes.
Glucotrack’s Continuous Blood Glucose Monitor (CBGM) is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. The Glucotrack CBGM is an Investigational Device and is limited by federal (or United States) law to investigational use.
For more information, please visithttp://www.glucotrack.com. Information on the Company’s website does not constitute a part of and is not incorporated by reference into this press release.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “anticipate”, “believe”, “expect”, “plan” and “will” are intended to identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, management. These statements relate only to events as of the date on which the statements are made, and Glucotrack undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. All of the forward-looking statements made in this press release are qualified by these cautionary statements, and there can be no assurance that the actual results anticipated by Glucotrack will be realized or, even if substantially realized, that they will have the expected consequences to or effects on us or our business or operations. Readers are cautioned that certain important factors may affect Glucotrack’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect Glucotrack’s results include, but are not limited to, the ability of Glucotrack to raise additional capital to finance its operations (whether through public or private equity offerings, debt financings, strategic collaborations or otherwise); risks relating to the receipt (and timing) of regulatory approvals (including U.S. Food and Drug Administration approval); risks relating to enrollment of patients in, and the conduct of, clinical trials; risks relating to Glucotrack’s future distribution agreements; risks relating to its ability to hire and retain qualified personnel, including sales and distribution personnel; and the additional risk factors described in Glucotrack’s filings with the U.S. Securities and Exchange Commission (the “SEC”), including its Annual Report on Form 10-K for the year ended December 31, 2024 as filed with the SEC on March 31, 2025.
| Investor Relations: | Media: |
| investors@glucotrack.com | GlucotrackPR@icrinc.com |
GLUCOTRACK INC.CONDENSED CONSOLIDATED BALANCE SHEETS(in thousands of US dollars except share data)
| In thousands of US dollars(except stock data) | ||||||||
| June 30, 2025 | December 31, 2024 | |||||||
| Unaudited | ||||||||
| Current Assets | ||||||||
| Cash and cash equivalents | $ | 9,555 | $ | 5,617 | ||||
| Other current assets | 522 | 151 | ||||||
| Total current assets | 10,077 | 5,768 | ||||||
| Operating lease right-of-use asset, net | 46 | 59 | ||||||
| Property and equipment, net | 87 | 95 | ||||||
| Restricted cash | - | 10 | ||||||
| TOTAL ASSETS | $ | 10,210 | $ | 5,932 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) | ||||||||
| Current Liabilities | ||||||||
| Accounts payable | $ | 2,644 | $ | 992 | ||||
| Operating lease liability, current | 27 | 26 | ||||||
| Convertible promissory notes | - | 5 | ||||||
| Other current liabilities | 414 | 252 | ||||||
| Total current liabilities | 3,085 | 1,275 | ||||||
| Non-Current Liabilities | ||||||||
| Derivative financial liabilities (Note 2F and Note 3B) | 5 | 17,421 | ||||||
| Operating lease liability, non-current | 19 | 33 | ||||||
| Loans from stockholders | 221 | 203 | ||||||
| Total liabilities | $ | 3,330 | $ | 18,932 | ||||
| Commitments and contingent liabilities (Note 4) | ||||||||
| Stockholders’ Equity (Deficit) | ||||||||
| Common Stock of $0.001 par value (“Common Stock”): | ||||||||
| 250,000,000 and 100,000,000 shares authorized as of June 30, 2025 and December 31, 2024, respectively; 899,410 and 13,409 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively | 1 | (*) | ||||||
| Additional paid-in capital | 150,649 | 119,230 | ||||||
| Receipts on account of shares | 228 | 228 | ||||||
| Accumulated other comprehensive income | 41 | (8 | ) | |||||
| Accumulated deficit | (144,039 | ) | (132,450 | ) | ||||
| Total stockholders’ equity (deficit) | 6,880 | (13,000 | ) | |||||
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) | $ | 10,210 | $ | 5,932 |
GLUCOTRACK INC.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS(in thousands of US dollars except share data) (unaudited)
| Six-monthperiod ended June 30, | Three-monthperiod ended June 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Operating expenses | ||||||||||||||||
| Research and development expenses | $ | 5,021 | $ | 5,737 | $ | 3,150 | $ | 3,589 | ||||||||
| General and administrative expenses | 2,963 | 1,535 | 1,464 | 802 | ||||||||||||
| Marketing expenses | 310 | 170 | 182 | 100 | ||||||||||||
| Total operating expenses | 8,294 | 7,442 | 4,796 | 4,491 | ||||||||||||
| Operating loss | 8,294 | 7,442 | 4,796 | 4,491 | ||||||||||||
| Other (income) expense | ||||||||||||||||
| Change in fair value of derivative Liabilities | 3,269 | - | (107 | ) | - | |||||||||||
| Other (income) expense, net | 92 | 96 | ||||||||||||||
| Finance income, net | (66 | ) | (26 | ) | (29 | ) | (2 | ) | ||||||||
| Net Loss | 11,589 | 7,416 | 4,756 | 4,489 | ||||||||||||
| Other comprehensive income: | ||||||||||||||||
| Foreign currency translation adjustment | (65 | ) | (6 | ) | (29 | ) | - | |||||||||
| Comprehensive loss for the period | $ | 11,524 | $ | 7,410 | $ | 4,727 | $ | 4,489 | ||||||||
| Basic and diluted net loss per common stock | $ | 34.81 | $ | 1,700 | $ | 9.62 | $ | 984 | ||||||||
| Weighted average number of common stock used in computing basic and diluted loss per common stock | 332,931 | 4,363 | 494,504 | 4,564 |